T. Maduskuie

发表

Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.

Y. Ru, T. Maduskuie, K. McNamara, 1998, Journal of medicinal chemistry.

Role of P-Glycoprotein and the Intestine in the Excretion of DPC 333 [(2R)-2-{(3R)-3-Amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide] in Rodents

T. Maduskuie, C. Garner, C. Decicco, 2008, Drug Metabolism and Disposition.

Pharmacokinetics and Pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-Amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a Potent and Selective Inhibitor of Tumor Necrosis Factor α-Converting Enzyme in Rodents, Dogs, Chimpanzees, and Humans

J. Trzăskos, T. Maduskuie, C. Garner, 2007, Drug Metabolism and Disposition.

Species-Specific Metabolism of SGX523 by Aldehyde Oxidase and the Toxicological Implications

T. Maduskuie, S. Diamond, J. Boer, 2010, Drug Metabolism and Disposition.

The de novo design and synthesis of cyclic urea inhibitors of factor Xa: optimization of the S4 ligand.

C. Dominguez, T. Maduskuie, R. Knabb, 2000, Bioorganic & medicinal chemistry letters.

INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ).

H. Koblish, P. Scherle, T. Maduskuie, 2019, ACS medicinal chemistry letters.

Design, synthesis, and structure--activity relationship studies for a new imidazole series of J774 macrophage specific acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors.

T. Maduskuie, J. Billheimer, E. Shimshick, 1995, Journal of medicinal chemistry.

Hydroxyacetophenone-derived antagonists of the peptidoleukotrienes.

T. Maduskuie, A. K. Willard, P. Bernstein, 1989, Journal of Medicinal Chemistry.

The de novo design and synthesis of cyclic urea inhibitors of factor Xa: initial SAR studies.

C. Dominguez, T. Maduskuie, R. Knabb, 1998, Bioorganic & medicinal chemistry letters.

Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles.

R. Keith, V. Matassa, T. Maduskuie, 1990, Journal of medicinal chemistry.

Synthesis and structure–activity relationship of a novel, achiral series of TNF-α converting enzyme inhibitors

J. Trzăskos, T. Maduskuie, B. W. King, 2004 .

Effect of DPC 333 [(2R)-2-{(3R)-3-Amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a Human Tumor Necrosis Factor α-Converting Enzyme Inhibitor, on the Disposition of Methotrexate: A Transporter-Based Drug-Drug Interaction Case Study

K. Brouwer, T. Maduskuie, C. Garner, 2007, Drug Metabolism and Disposition.

EFFECT OF DPC 333, A HUMAN TUMOR NECROSIS FACTOR α CONVERTING ENZYME INHIBITOR, ON THE DISPOSITION OF METHOTREXATE: A TRANSPORTER BASED DRUG-DRUG INTERACTION CASE STUDY

K. Brouwer, T. Maduskuie, C. Garner, 2007 .

The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies

Jun Yu Li, R. Wynn, X. Liu, 2018, Clinical Cancer Research.

Abstract 2671: INCB050465, a novel PI3Kδ inhibitor, synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL

H. Koblish, P. Scherle, T. Maduskuie, 2015 .

Abstract 5071: Preclinical characterization of the potent and selective BET inhibitor INCB057643 in models of hematologic malignancies

R. Wynn, X. Liu, X. Wen, 2017 .

Acyl CoA:cholesterol acyltransferase (ACAT) inhibitors: synthesis and structure-activity relationship studies of a new series of trisubstituted imidazoles.

T. Maduskuie, J. Billheimer, C. Higley, 1994, Journal of medicinal chemistry.

Acyl CoA:cholesterol acyltransferase (ACAT) inhibitors: ureas bearing heterocyclic groups bioisosteric for an imidazole

T. Maduskuie, J. Billheimer, C. Higley, 1995 .

Acyl CoA: Cholesterol Acyltransferase (ACAT) Inhibitors: Ureas Bearing Heterocyclic Groups Bioisosteric for an Imidazole.

T. Maduskuie, J. Billheimer, C. Higley, 1995 .

Synthesis and evaluation of succinoyl-caprolactam γ-secretase inhibitors

Marcie A. Glicksman, M. Glicksman, D. Seiffert, 2006 .

Abstract 4904: The BET inhibitor INCB054329 enhances the activity of checkpoint modulation in syngeneic tumor models

H. Koblish, Yue Zhang, M. Stubbs, 2016 .

Abstract 3780: Activity of the BET inhibitor INCB054329 in models of lymphoma

M. Stubbs, M. Favata, P. Scherle, 2016 .

Abstract 3523: Discovery of a novel BET inhibitor INCB054329

R. Wynn, X. Liu, Jun Li, 2015 .

Synthesis and in vitro LTD4 antagonist activity of bicyclic and monocyclic cyclopentylurethane and cyclopentylacetamide N-arylsulfonyl amides.

V. Matassa, T. Maduskuie, R. Krell, 1990, Journal of medicinal chemistry.

Abstract C103: The combination of PI3kδ-selective inhibition and immunomodulation shows efficacy in solid tumor models

H. Koblish, Yue Zhang, P. Scherle, 2015 .